Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BCL9 | O00512 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23122705 | 0.99 | HSD11B1 (0.41) | HSD11B1NR3C1PGRSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL30008988 | 0.99 | HSD11B1 (0.41) | HSD11B1NR3C1PGRSLC6A4KCNH2 | |
| Trifluoroacetic Acid SCHEMBL31696980 | 0.94 | PKM (0.46) | HSD11B1NR3C1PGRSLC6A4KCNH2 | |
| SCHEMBL21409284 | 0.91 | NR3C1 (0.42) | HSD11B1NR3C1PGRSLC6A4KCNH2 | |
| SCHEMBL23134536 | 0.91 | NR3C1 (0.42) | HSD11B1NR3C1PGRSLC6A4KCNH2 | |
| SCHEMBL31255602 | 0.91 | L3MBTL3 (0.44) | HSD11B1NR3C1PGRSLC6A4KCNH2 | |
| SCHEMBL31255390 | 0.89 | GAA (0.44) | HSD11B1NR3C1PGRSLC6A4KCNH2 | |
| SCHEMBL23122011 | 0.89 | GFER (0.44) | HSD11B1KMT2AALDH1A1BCL9CTNNB1 | |
| SCHEMBL30009532 | 0.89 | GFER (0.44) | HSD11B1KMT2AALDH1A1BCL9CTNNB1 | |
| SCHEMBL24735010 | 0.88 | NR3C1 (0.47) | NR3C1PGRSLC6A4KCNH2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2025-10-14 | — | — | US | disclosed |
| WO-2024240840-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | BEACTICA THERAPEUTICS AB (SE) | 2024-11-28 | — | — | WO | disclosed |
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2024-11-21 | — | — | US | disclosed |
| EP-4395828-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023031801-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4041724-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114521196-A | Bifunctional group degradation agent and use method thereof | 诺华股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3774804-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936498-A | N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives | 诺华股份有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019186343-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | HSD11B1 972/4885NR3C1 1860/4885PGR 2711/4885 |
| US-20240382600-A1 | BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER | YAP1, JMJD7, TOR1AIP1 | HSD11B1 3291/4885NR3C1 3889/4885PGR 4303/4885 |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | HSD11B1 3496/4885NR3C1 3955/4885PGR 2332/4885 |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | BTK, ABL1, LYN | HSD11B1 1464/4885NR3C1 1859/4885PGR 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.